Surrozen: FDA clears IND for SZN-8141

What happened Surrozen announced on Oct 2, 2026 that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SZN-8141, with the IND going into effect following the completion of the statutory 30-day review period. SZN-8141 is described in the filing as a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME). The company reported it expects to dose the first patient in DUET, a Phase 1b/2a clinical study evaluating SZN-8141 in patients with DME, in the fourth quarter of 2026, with initial data expected in the second half of 2027.

Key details

• FDA clearance of the SZN-8141 IND satisfies the second closing milestone under Surrozen’s Mar 2025 two-tranche private placement.
• The second closing is expected to provide approximately $95,100,000 in gross proceeds, before deducting placement agent fees and other expenses.
• The second closing is expected to occur on or about Oct 20, 2026, subject to satisfaction of applicable closing conditions.
• Following the second closing, Surrozen expects to file a new registration statement on Form S-3 to register resale of the shares and shares issuable upon exercise of pre-funded warrants and Series E common stock warrants, with the registration statement required to be filed no later than 30 calendar days following the closing.

Why it may matter This Current Report on Form 8-K is Item 8.01, Other Events, and it covers the FDA clearance of the SZN-8141 IND and related financing milestones under the Mar 2025 private placement. This filing does not show why the insider traded or why the company acted.